Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people...
33 KB (3,121 words) - 08:30, 1 July 2024
neuroprotection. The drugs clopidogrel (Plavix), prasugrel (Efient, Effient), ticagrelor (Brilinta), and cangrelor (Kengreal) bind to this receptor and are marketed...
10 KB (992 words) - 18:32, 10 December 2023
in-vivo to inhibit the P2Y12 receptor. On the other hand, novel drugs like ticagrelor (Brilinta®) and cangrelor (Kengrexal®) are non-thienopyridines and reversibly...
46 KB (5,282 words) - 08:16, 30 March 2024
of aspirin plus an ADP/P2Y inhibitor (such as clopidogrel, prasugrel, ticagrelor, or another) is used to obtain greater effectiveness than with either...
18 KB (1,752 words) - 10:58, 11 August 2024
trials to function as a reversal agent for the anti–blood clotting drug ticagrelor (which acts as a P2Y12 inhibitor and is sold under the brand name Brilinta...
4 KB (200 words) - 00:21, 29 January 2023
order to avoid confusion with the blood-thinning medication Brilinta (ticagrelor). Other brand names include Torvox, Vantaxa, Voxigain, and Trivoxetin...
56 KB (4,794 words) - 11:06, 17 August 2024
medications: cisapride, pimozide, astemizole, terfenadine, ergotamine, ticagrelor, ranolazine or dihydroergotamine is not recommended. It should not be...
27 KB (2,574 words) - 07:54, 1 July 2024
indefinitely, as well as another antiplatelet agent such as clopidogrel or ticagrelor ("dual antiplatelet therapy" or DAPT) for up to twelve months. If someone...
130 KB (13,860 words) - 08:10, 17 August 2024
with presumed ACS are typically treated with aspirin, clopidogrel or ticagrelor, nitroglycerin, and if the chest discomfort persists morphine. Other analgesics...
31 KB (3,369 words) - 20:25, 17 July 2024
assessing cangrelor administration in conjunction with either prasugrel or ticagrelor. Cangrelor been approved for adults undergoing percutaneous coronary intervention...
15 KB (1,150 words) - 05:23, 3 March 2024
Ip5I MRS-2179 MRS-2211 MRS-2279 MRS-2395 MRS-2500 MRS-2578 NF-157 NF-340 PIT PPADS Prasugrel PSB-0739 RB-2 Regrelor Suramin Ticagrelor Ticlopidine UDP...
32 KB (3,346 words) - 12:19, 4 July 2024
advent of newer and safer antiplatelet drugs such as clopidogrel and ticagrelor, its use remained limited. It was patented in 1973 and approved for medical...
18 KB (1,724 words) - 18:25, 20 June 2024
Ip5I MRS-2179 MRS-2211 MRS-2279 MRS-2395 MRS-2500 MRS-2578 NF-157 NF-340 PIT PPADS Prasugrel PSB-0739 RB-2 Regrelor Suramin Ticagrelor Ticlopidine UDP...
236 KB (24,256 words) - 17:37, 17 August 2024
Sebelipase alfa Selumetinib Sodium zirconium cyclosilicate Tamoxifen Ticagrelor Tixagevimab/cilgavimab Trastuzumab deruxtecan Vandetanib Vaxzevria Ximelagatran...
56 KB (5,566 words) - 02:21, 16 August 2024
Ip5I MRS-2179 MRS-2211 MRS-2279 MRS-2395 MRS-2500 MRS-2578 NF-157 NF-340 PIT PPADS Prasugrel PSB-0739 RB-2 Regrelor Suramin Ticagrelor Ticlopidine UDP...
200 KB (19,953 words) - 16:12, 16 August 2024
Sebelipase alfa Selumetinib Sodium zirconium cyclosilicate Tamoxifen Ticagrelor Tixagevimab/cilgavimab Trastuzumab deruxtecan Vandetanib Vaxzevria Ximelagatran...
41 KB (3,439 words) - 18:35, 12 August 2024
Ip5I MRS-2179 MRS-2211 MRS-2279 MRS-2395 MRS-2500 MRS-2578 NF-157 NF-340 PIT PPADS Prasugrel PSB-0739 RB-2 Regrelor Suramin Ticagrelor Ticlopidine UDP...
20 KB (2,024 words) - 16:36, 29 July 2024
Sebelipase alfa Selumetinib Sodium zirconium cyclosilicate Tamoxifen Ticagrelor Tixagevimab/cilgavimab Trastuzumab deruxtecan Vandetanib Vaxzevria Ximelagatran...
31 KB (2,605 words) - 23:47, 9 July 2024
Ip5I MRS-2179 MRS-2211 MRS-2279 MRS-2395 MRS-2500 MRS-2578 NF-157 NF-340 PIT PPADS Prasugrel PSB-0739 RB-2 Regrelor Suramin Ticagrelor Ticlopidine UDP...
39 KB (4,027 words) - 14:39, 17 August 2024
Ip5I MRS-2179 MRS-2211 MRS-2279 MRS-2395 MRS-2500 MRS-2578 NF-157 NF-340 PIT PPADS Prasugrel PSB-0739 RB-2 Regrelor Suramin Ticagrelor Ticlopidine UDP...
26 KB (2,467 words) - 22:10, 5 June 2024
Ip5I MRS-2179 MRS-2211 MRS-2279 MRS-2395 MRS-2500 MRS-2578 NF-157 NF-340 PIT PPADS Prasugrel PSB-0739 RB-2 Regrelor Suramin Ticagrelor Ticlopidine UDP...
37 KB (3,698 words) - 02:33, 5 August 2024
Sebelipase alfa Selumetinib Sodium zirconium cyclosilicate Tamoxifen Ticagrelor Tixagevimab/cilgavimab Trastuzumab deruxtecan Vandetanib Vaxzevria Ximelagatran...
79 KB (6,533 words) - 11:42, 20 June 2024
Ip5I MRS-2179 MRS-2211 MRS-2279 MRS-2395 MRS-2500 MRS-2578 NF-157 NF-340 PIT PPADS Prasugrel PSB-0739 RB-2 Regrelor Suramin Ticagrelor Ticlopidine UDP...
36 KB (3,297 words) - 19:46, 10 August 2024
Ip5I MRS-2179 MRS-2211 MRS-2279 MRS-2395 MRS-2500 MRS-2578 NF-157 NF-340 PIT PPADS Prasugrel PSB-0739 RB-2 Regrelor Suramin Ticagrelor Ticlopidine UDP...
79 KB (7,766 words) - 03:04, 14 August 2024
Sebelipase alfa Selumetinib Sodium zirconium cyclosilicate Tamoxifen Ticagrelor Tixagevimab/cilgavimab Trastuzumab deruxtecan Vandetanib Vaxzevria Ximelagatran...
86 KB (7,929 words) - 11:30, 5 August 2024
Sebelipase alfa Selumetinib Sodium zirconium cyclosilicate Tamoxifen Ticagrelor Tixagevimab/cilgavimab Trastuzumab deruxtecan Vandetanib Vaxzevria Ximelagatran...
42 KB (3,794 words) - 22:28, 15 August 2024
combined with an ADP receptor inhibitor, such as clopidogrel, prasugrel, or ticagrelor to prevent blood clots. This is called dual antiplatelet therapy (DAPT)...
152 KB (16,388 words) - 15:42, 16 August 2024
2021 a higher risk of stroke at 90 days was found with clopidogrel than ticagrelor, which does not require metabolic conversion, among Han Chinese CYP2C19...
39 KB (3,879 words) - 02:14, 11 August 2024
Sebelipase alfa Selumetinib Sodium zirconium cyclosilicate Tamoxifen Ticagrelor Tixagevimab/cilgavimab Trastuzumab deruxtecan Vandetanib Vaxzevria Ximelagatran...
31 KB (2,739 words) - 18:31, 9 August 2024
Ip5I MRS-2179 MRS-2211 MRS-2279 MRS-2395 MRS-2500 MRS-2578 NF-157 NF-340 PIT PPADS Prasugrel PSB-0739 RB-2 Regrelor Suramin Ticagrelor Ticlopidine UDP...
32 KB (3,305 words) - 22:21, 6 May 2024